Avastin Safety Questions In Wet AMD Linger With Two-Year CATT Results

Over two years, serious adverse events occurred at a 40% rate for patients treated with Avastin and at a 32% rate for patients receiving Lucentis, CATT researchers report in an article published in the journal Ophthalmology.